Hetero gets emergency use nod to make Roche’s COVID-19 drug

Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira
Read Article

Hetero yesterday said it has received emergency use approval from the country’s health authorities to make a generic version of Roche Holding’s COVID-19 drug.

Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira. Tocilizumab has been facing a global shortage as the highly contagious COVID-19 Delta variant drives up cases in several countries.

COVID-19 cases in India have declined from levels hit during the second wave in April and May, although health experts believe that the country should brace for a third wave by October.

Roche’s arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.

Tocira will be made by Hetero’s unit at its Hyderabad facility.

Hetero, which makes COVID-19 treatments like remdesivir and favipiravir, had also sought emergency approval for Merck’s COVID-19 drug molnupiravir in July.

483 reportCOVID-19 drugemergency-use drugHetero PharmaMerck PharmamolnupiravirremdesivirRocheTocilizumabTocira
Comments (0)
Add Comment